person · Reporting owner

Ryan Jason

Disclosed activity across 5 companies

Tapewire entity: 36008
SEC CIK: 0001585017

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813	See Remarks	February 10, 2020	February 12, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Dianthus Therapeutics, Inc. /DE/

Report date February 10, 2020 · Filed February 12, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.28 · Expires 2030-02-09	Direct	75,000	Reported balance After 2020-02-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-02-10 · Grant · Acquired 75,000 · Balance 75,000 F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Foundation Medicine, Inc.

Report date July 31, 2018 · Filed August 02, 2018

Section 16 reporting ended · disclosed 2018-08-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2018-07-31 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2018-07-31 · Other · Disposed 6,955 · Balance 42,215 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. Row 2 · 2018-07-31 · Other · Disposed 42,215 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units.
stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.12 · Expires 2023-05-21	Direct	0	Reported balance After 2018-07-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-07-31 · Other · Disposed 1,562 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F4: The amount reported represents the number of vested stock options cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share minus the per share exercise price of the vested stock options, multiplied by (2) the number of shares represented by such vested stock options, without interest and less any required withholding taxes. F5: This option was granted on May 21, 2013 and vested in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company.

F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche.

F3: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units.

F4: The amount reported represents the number of vested stock options cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share minus the per share exercise price of the vested stock options, multiplied by (2) the number of shares represented by such vested stock options, without interest and less any required withholding taxes.

F5: This option was granted on May 21, 2013 and vested in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018.

GeneDx Holdings Corp.

Report date June 18, 2026 · Filed June 23, 2026

Section 16 reporting ended · disclosed 2026-06-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	15,480	Reported balance After 2026-06-18 transaction · row 1 1 source row Row 1 · 2026-06-18 · Exercise / conversion · Acquired 3,576 · Balance 15,480 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-18 · Exercise / conversion · Disposed 3,576 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
Class A Common StockSEC Table I · non-derivative	IndirectBy Jason Ryan 2024 GRAT	103,284	Reported balance Holding disclosure · report date 2026-06-18 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 103,284 F2: The securities in this row are held directly by the Jason Ryan 2024 GRAT U/A DTD 11/7/2024, of which the Reporting Person is trustee and sole annuitant.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2: The securities in this row are held directly by the Jason Ryan 2024 GRAT U/A DTD 11/7/2024, of which the Reporting Person is trustee and sole annuitant.

F3: The entire award vested or vests on the earlier of the: (i) date of the 2026 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.

Singular Genomics Systems, Inc.

Report date February 21, 2025 · Filed February 25, 2025

Section 16 reporting ended · disclosed 2025-02-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $672.90 · Expires 2031-05-05	Direct	Reported balance After 2025-02-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-02-21 · Disposition to issuer · Disposed 1,333 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F2: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.80 · Expires 2032-05-26	Direct	Reported balance After 2025-02-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-02-21 · Disposition to issuer · Disposed 1,541 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F2: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.80 · Expires 2033-05-25	Direct	Reported balance After 2025-02-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-02-21 · Disposition to issuer · Disposed 2,466 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F2: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.16 · Expires 2034-05-29	Direct	Reported balance After 2025-02-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-02-21 · Disposition to issuer · Disposed 2,466 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F2: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.

F2: As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.

SomaLogic, Inc.

Report date January 05, 2024 · Filed January 10, 2024

Section 16 reporting ended · disclosed 2024-01-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2033-06-07	Direct	Reported balance After 2024-01-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-01-05 · Disposition to issuer · Disposed 185,400 · Balance 0 F2: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and F3: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"), F4: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F1: The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2033-06-07	Direct	Reported balance After 2024-01-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-01-05 · Disposition to issuer · Disposed 14,650 · Balance 0 F2: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and F3: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"), F4: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions. F5: The option shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date.
Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security	Direct	Reported balance After 2024-01-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-01-05 · Disposition to issuer · Disposed 3,400 · Balance 0 F6: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration. F8: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time. F7: The RSUs shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests as to 1/4th of the total grant on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is 100% vested, subject to the continued service of the Reporting Person on each vesting date.

F2: On October 4, 2023, SomaLogic, Inc., a Delaware corporation (the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Standard BioTools Inc., a Delaware corporation ("Parent"), and Martis Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent (the "Merger Sub"). Pursuant to the Merger Agreement, on January 5, 2024, Merger Sub merged with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the "Merger"); and

F3: (Continued from Footnote 2) each option to purchase Company Common Stock (a "Company Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 shares (the "Exchange Ratio") of the Parent's common stock, par value $0.001 (the "Parent Common Stock"),

F4: (Continued from Footnote 3) rounded down to the nearest whole number of shares of the Parent Common Stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Company Option by the Exchange Ratio, rounded up to the nearest whole cent. Each such Company Option shall continue to have, and be subject to, the same terms and conditions applicable to such Company Option immediately prior to the Effective Time, including vesting terms and provisions.

F5: The option shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date.

F6: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company Common Stock upon settlement for no consideration.

F7: The RSUs shall be 100% vested on June 8, 2024, subject to the continued service of the Reporting Person on such vesting date.

F8: Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Parent Common Stock rounded to the next nearest whole share. Except as noted above, each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such Company RSU immediately prior to the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 15, 2022 Filed Oct 18, 2022 22:36 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	Exercise / conversionClass A Common Stock	4,278	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-054000 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document
May 26, 2022 Filed May 31, 2022 21:05 UTC	Singular Genomics Systems, Inc. OMIC · Entity 82741	GrantStock Option (Right to Buy) · Derivative	46,250	$0.00 Strike: $2.86	$0.00	Disclosure SEC source: 0001209191-22-033020 · doc4.xml · derivative · entry 1 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 Underlying: Common Stock · 46,250 shares Expires 2032-05-26 F1 · derivative.exercise_date: The option shares vest and become exercisable upon the earlier of the 2023 Stockholder Annual Meeting or May 26, 2023. Read SEC document
April 27, 2022 Filed May 13, 2022 00:23 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	Exercise / conversionRestricted Stock Unit · Derivative	12,836	$0.00	$0.00	Disclosure SEC source: 0001209191-22-028691 · doc4.xml · derivative · entry 2 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 12,836 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs will vest on the earlier of (i) the date of the next annual meeting of the Company's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the non-employee director continues to provide services to the Company through such vesting date. F2 · derivative.expiration_date: The RSUs will vest on the earlier of (i) the date of the next annual meeting of the Company's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the non-employee director continues to provide services to the Company through such vesting date. Read SEC document
April 27, 2022 Filed May 13, 2022 00:23 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	Exercise / conversionClass A Common Stock	12,836	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-028691 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document
January 18, 2022 Filed Jan 20, 2022 23:45 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	GrantRestricted Stock Unit · Derivative	247,525	$0.00	$0.00	Disclosure SEC source: 0001209191-22-004176 · doc4.xml · derivative · entry 2 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,525 Underlying: Class A Common Stock · 247,525 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A common stock upon settlement for no consideration. F1 · derivative.exercise_date: 100% of the underlying awards shall become vested and exercisable on the earlier of (A) December 31, 2022, and (B) a change in control of the Issuer, subject to the Reporting Person's continued service to the Issuer on such earlier date, or upon a termination of the Reporting Person's service as Executive Chairman of the Board under certain circumstances. F1 · derivative.expiration_date: 100% of the underlying awards shall become vested and exercisable on the earlier of (A) December 31, 2022, and (B) a change in control of the Issuer, subject to the Reporting Person's continued service to the Issuer on such earlier date, or upon a termination of the Reporting Person's service as Executive Chairman of the Board under certain circumstances. Read SEC document
January 18, 2022 Filed Jan 20, 2022 23:45 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	GrantStock Option (right to buy) · Derivative	429,730	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0001209191-22-004176 · doc4.xml · derivative · entry 1 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,730 Underlying: Class A Common Stock · 429,730 shares Expires 2032-01-17 F1 · derivative.exercise_date: 100% of the underlying awards shall become vested and exercisable on the earlier of (A) December 31, 2022, and (B) a change in control of the Issuer, subject to the Reporting Person's continued service to the Issuer on such earlier date, or upon a termination of the Reporting Person's service as Executive Chairman of the Board under certain circumstances. Read SEC document
October 15, 2021 Filed Oct 19, 2021 23:24 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	GrantRestricted Stock Unit · Derivative	12,836	$0.00	$0.00	Disclosure SEC source: 0001209191-21-061026 · doc4.xml · derivative · entry 4 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,836 Underlying: Class A Common Stock · 12,836 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs will vest in equal annual installments over the three-year period following the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. F4 · derivative.expiration_date: The RSUs will vest in equal annual installments over the three-year period following the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document
October 15, 2021 Filed Oct 19, 2021 23:24 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	GrantRestricted Stock Unit · Derivative	12,836	$0.00	$0.00	Disclosure SEC source: 0001209191-21-061026 · doc4.xml · derivative · entry 3 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,836 Underlying: Class A Common Stock · 12,836 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F1 · derivative.exercise_date: The stock options and restricted stock units ("RSUs") will vest on the earlier of (i) the date of the next annual meeting of the Issuer's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the Reporting Person continues to provide services to the Issuer through such vesting date. F1 · derivative.expiration_date: The stock options and restricted stock units ("RSUs") will vest on the earlier of (i) the date of the next annual meeting of the Issuer's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the Reporting Person continues to provide services to the Issuer through such vesting date. Read SEC document
October 15, 2021 Filed Oct 19, 2021 23:24 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	GrantEmployee Stock Option (Right to Buy) · Derivative	22,286	$0.00 Strike: $7.79	$0.00	Disclosure SEC source: 0001209191-21-061026 · doc4.xml · derivative · entry 2 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,286 Underlying: Class A Common Stock · 22,286 shares Expires 2031-10-14 F2 · derivative.exercise_date: The stock option shall vest as of 1/36 of the total shares monthly beginning on November 15, 2021 until fully vested, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date. Read SEC document
October 15, 2021 Filed Oct 19, 2021 23:24 UTC	GeneDx Holdings Corp. SMFR · Entity 1634	GrantEmployee Stock Option (Right to Buy) · Derivative	22,286	$0.00 Strike: $7.79	$0.00	Disclosure SEC source: 0001209191-21-061026 · doc4.xml · derivative · entry 1 Ryan Jason · CIK 0001585017 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,286 Underlying: Class A Common Stock · 22,286 shares Expires 2031-10-14 F1 · derivative.exercise_date: The stock options and restricted stock units ("RSUs") will vest on the earlier of (i) the date of the next annual meeting of the Issuer's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the Reporting Person continues to provide services to the Issuer through such vesting date. Read SEC document
February 10, 2020 Filed Feb 12, 2020 22:15 UTC	Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813	GrantStock Option (Right to Buy) · Derivative	75,000	$0.00 Strike: $12.28	$0.00	Disclosure SEC source: 0000899243-20-004316 · doc4.xml · derivative · entry 1 Ryan Jason · CIK 0001585017 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-02-09 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020. Read SEC document
January 02, 2019 Filed Jan 4, 2019 21:16 UTC	Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813	GrantStock Option (Right to Buy) · Derivative	329,379	$0.00 Strike: $6.00	$0.00	Disclosure SEC source: 0000899243-19-000527 · doc4.xml · derivative · entry 1 Ryan Jason · CIK 0001585017 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,379 Underlying: Common Stock · 329,379 shares Expires 2029-01-01 F1 · derivative.exercise_date: This option shall vest and become exerciseable over four years, with 25% of this option vesting on January 1, 2020, and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document
July 31, 2018 Filed Aug 2, 2018 16:09 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Otherstock option (right to buy) · Derivative	1,562	$0.00 Strike: $7.12	$0.00	Disclosure SEC source: 0001209191-18-044936 · doc4.xml · derivative · entry 3 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,562 shares Expires 2023-05-21 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F4 · shares: The amount reported represents the number of vested stock options cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share minus the per share exercise price of the vested stock options, multiplied by (2) the number of shares represented by such vested stock options, without interest and less any required withholding taxes. F5 · derivative.exercise_date: This option was granted on May 21, 2013 and vested in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018. Read SEC document
July 31, 2018 Filed Aug 2, 2018 16:09 UTC	Foundation Medicine, Inc. FMI · Entity 164565	OtherCommon Stock	42,215	$137.00	$5,783,455.00	Disclosure SEC source: 0001209191-18-044936 · doc4.xml · nonDerivative · entry 2 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3 · shares: The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units. Read SEC document
July 31, 2018 Filed Aug 2, 2018 16:09 UTC	Foundation Medicine, Inc. FMI · Entity 164565	OtherCommon Stock	6,955	$137.00	$952,835.00	Disclosure SEC source: 0001209191-18-044936 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,215 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2 · shares: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. Read SEC document
July 02, 2018 Filed Jul 5, 2018 16:10 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	3,403	$136.66	$465,053.98	Disclosure SEC source: 0001209191-18-041561 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,170 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on July 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on (1) April 1, 2016 in Table I of the Form 4 filed on April 6, 2016, (2) May 1, 2017 in Table I of the Form 4 filed on May 3, 2017 and (3) April 1, 2018 in Table I of the Form 4 filed on April 3, 2018. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting events related to this securities sale. Read SEC document
April 16, 2018 Filed Apr 18, 2018 16:08 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	3,449	$74.30	$256,260.70	Disclosure SEC source: 0001209191-18-025357 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,573 F1 · shares: The sale of these shares were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.00 to $79.55, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
April 03, 2018 Filed Apr 5, 2018 16:15 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	1	$72.40	$72.40	Disclosure SEC source: 0001209191-18-024051 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,022 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on April 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document
April 02, 2018 Filed Apr 3, 2018 16:13 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	3,030	$74.87	$226,856.10	Disclosure SEC source: 0001209191-18-022900 · doc4.xml · nonDerivative · entry 3 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,023 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on April 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F4 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.60 to $75.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F5 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document
April 02, 2018 Filed Apr 3, 2018 16:13 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	3,109	$77.55	$241,102.95	Disclosure SEC source: 0001209191-18-022900 · doc4.xml · nonDerivative · entry 2 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,053 F2 · shares: The sale of these shares were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2017. Read SEC document
April 01, 2018 Filed Apr 3, 2018 16:13 UTC	Foundation Medicine, Inc. FMI · Entity 164565	GrantCommon Stock	12,932	$78.75	$1,018,395.00	Disclosure SEC source: 0001209191-18-022900 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,162 F1 · shares: Represents restricted stock units issued pursuant to a Restricted Stock Unit Award Agreement and the Issuer's 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in equal quarterly installments over a three-year period with the first installment vesting on July 1, 2018. Read SEC document
March 15, 2018 Filed Mar 19, 2018 16:17 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock (right to buy) · Derivative	7,853	$0.00 Strike: $29.63	$0.00	Disclosure SEC source: 0001209191-18-020566 · doc4.xml · derivative · entry 6 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,853 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on February 6, 2014 and vested in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018. Read SEC document
March 15, 2018 Filed Mar 19, 2018 16:17 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock (right to buy) · Derivative	7,147	$0.00 Strike: $29.63	$0.00	Disclosure SEC source: 0001209191-18-020566 · doc4.xml · derivative · entry 5 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,147 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on February 6, 2014 and vested in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018. Read SEC document
March 15, 2018 Filed Mar 19, 2018 16:17 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	7,853	$78.26	$614,575.78	Disclosure SEC source: 0001209191-18-020566 · doc4.xml · nonDerivative · entry 4 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,230 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.50 to $79.45, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
March 15, 2018 Filed Mar 19, 2018 16:17 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock	7,853	$29.63	$232,684.39	Disclosure SEC source: 0001209191-18-020566 · doc4.xml · nonDerivative · entry 3 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 15, 2018 Filed Mar 19, 2018 16:17 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	7,147	$78.26	$559,324.22	Disclosure SEC source: 0001209191-18-020566 · doc4.xml · nonDerivative · entry 2 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,230 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.50 to $79.45, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
March 15, 2018 Filed Mar 19, 2018 16:17 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock	7,147	$29.63	$211,765.61	Disclosure SEC source: 0001209191-18-020566 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 15, 2018 Filed Feb 20, 2018 16:05 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock (right to buy) · Derivative	15,000	$0.00 Strike: $29.63	$0.00	Disclosure SEC source: 0001209191-18-011252 · doc4.xml · derivative · entry 3 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,147 Underlying: Common Stock · 15,000 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on February 6, 2014 and vested in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018. Read SEC document
February 15, 2018 Filed Feb 20, 2018 16:05 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	15,000	$67.53	$1,012,950.00	Disclosure SEC source: 0001209191-18-011252 · doc4.xml · nonDerivative · entry 2 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,230 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.55 to $68.85, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
February 15, 2018 Filed Feb 20, 2018 16:05 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock	15,000	$29.63	$444,450.00	Disclosure SEC source: 0001209191-18-011252 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 16, 2018 Filed Jan 18, 2018 16:05 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock (right to buy) · Derivative	20,000	$0.00 Strike: $29.63	$0.00	Disclosure SEC source: 0001209191-18-004231 · doc4.xml · derivative · entry 4 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,147 Underlying: Common Stock · 20,000 shares Expires 2024-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on February 6, 2014 and vested in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018. Read SEC document
January 16, 2018 Filed Jan 18, 2018 16:05 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	20,000	$64.38	$1,287,600.00	Disclosure SEC source: 0001209191-18-004231 · doc4.xml · nonDerivative · entry 3 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,230 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.65 to $68.65, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
January 16, 2018 Filed Jan 18, 2018 16:05 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock	20,000	$29.63	$592,600.00	Disclosure SEC source: 0001209191-18-004231 · doc4.xml · nonDerivative · entry 2 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 16, 2018 Filed Jan 18, 2018 16:05 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	1,035	$64.38	$66,633.30	Disclosure SEC source: 0001209191-18-004231 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,230 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2017. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.65 to $68.65, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
January 02, 2018 Filed Jan 3, 2018 17:19 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	944	$64.00	$60,416.00	Disclosure SEC source: 0001209191-18-001139 · doc4.xml · nonDerivative · entry 2 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,265 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on January 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.73 to $64.12, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F4 · balance_after: The reporting person previously reported the restricted stock units granted to the reporting person on May 1, 2017 in Table I of the Form 4 filed on May 3, 2017. As such, no adjustment to the reporting persons beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document
January 02, 2018 Filed Jan 3, 2018 17:19 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	1,392	$64.00	$89,088.00	Disclosure SEC source: 0001209191-18-001139 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,209 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on January 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.73 to $64.12, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F3 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document
December 05, 2017 Filed Dec 7, 2017 16:05 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionstock option (right to buy) · Derivative	18,688	$0.00 Strike: $7.12	$0.00	Disclosure SEC source: 0001209191-17-064399 · doc4.xml · derivative · entry 6 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,562 Underlying: Common Stock · 18,688 shares Expires 2023-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on May 21, 2013 and vests in equal quarterly installments beginning on April 1, 2014 until fully vested on January 1, 2018. Read SEC document
December 05, 2017 Filed Dec 7, 2017 16:05 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionstock option (right to buy) · Derivative	3,038	$0.00 Strike: $0.08	$0.00	Disclosure SEC source: 0001209191-17-064399 · doc4.xml · derivative · entry 5 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,038 shares Expires 2021-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on June 15, 2011. Twenty-five percent vested on May 16, 2012 and an additional 6.25% vested in equal quarterly installments until fully vested on May 16, 2015. Read SEC document
December 05, 2017 Filed Dec 7, 2017 16:05 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	18,688	$61.26	$1,144,826.88	Disclosure SEC source: 0001209191-17-064399 · doc4.xml · nonDerivative · entry 4 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,601 F1 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.35 to $62.85, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
December 05, 2017 Filed Dec 7, 2017 16:05 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock	18,688	$7.12	$133,058.56	Disclosure SEC source: 0001209191-17-064399 · doc4.xml · nonDerivative · entry 3 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 05, 2017 Filed Dec 7, 2017 16:05 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	3,038	$61.26	$186,107.88	Disclosure SEC source: 0001209191-17-064399 · doc4.xml · nonDerivative · entry 2 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,601 F1 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.35 to $62.85, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
December 05, 2017 Filed Dec 7, 2017 16:05 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Exercise / conversionCommon Stock	3,038	$0.08	$243.04	Disclosure SEC source: 0001209191-17-064399 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 02, 2017 Filed Nov 6, 2017 16:02 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	9,731	$50.00	$486,550.00	Disclosure SEC source: 0001209191-17-059395 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,601 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document
October 12, 2017 Filed Oct 16, 2017 16:10 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	1,152	$45.05	$51,897.60	Disclosure SEC source: 0001209191-17-057008 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,332 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. The sale of a portion of these shares were effected to cover tax liabilities of the reporting person in connection with the vesting and release of restricted stock units. F2 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document
October 02, 2017 Filed Oct 4, 2017 16:05 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	1,325	$38.80	$51,410.00	Disclosure SEC source: 0001209191-17-055747 · doc4.xml · nonDerivative · entry 2 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,484 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on October 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.46 to $38.80, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F4 · balance_after: The reporting person previously reported the restricted stock units granted to the reporting person on May 1, 2017 in Table I of the Form 4 filed on May 3, 2017. As such, no adjustment to the reporting persons beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document
October 02, 2017 Filed Oct 4, 2017 16:05 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	1,829	$38.80	$70,965.20	Disclosure SEC source: 0001209191-17-055747 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,809 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on October 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.46 to $38.80, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F3 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document
July 13, 2017 Filed Jul 17, 2017 16:02 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	5,084	$39.77	$202,190.68	Disclosure SEC source: 0001209191-17-045331 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,638 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. The sale of a portion of these shares were effected to cover tax liabilities of the reporting person in connection with the vesting and release of restricted stock units. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.30 to $40.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Read SEC document
July 06, 2017 Filed Jul 7, 2017 16:04 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	1,308	$38.84	$50,802.72	Disclosure SEC source: 0001209191-17-044363 · doc4.xml · nonDerivative · entry 3 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,722 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on July 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $36.85 to $40.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F6 · balance_after: The reporting person previously reported the restricted stock units granted to the reporting person on May 1, 2017 in Table I of the Form 4 filed on May 3, 2017. As such, no adjustment to the reporting persons beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document
July 06, 2017 Filed Jul 7, 2017 16:04 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	1,806	$38.84	$70,145.04	Disclosure SEC source: 0001209191-17-044363 · doc4.xml · nonDerivative · entry 2 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,030 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on July 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $36.85 to $40.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F5 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document
July 06, 2017 Filed Jul 7, 2017 16:04 UTC	Foundation Medicine, Inc. FMI · Entity 164565	SaleCommon Stock	3,569	$38.84	$138,619.96	Disclosure SEC source: 0001209191-17-044363 · doc4.xml · nonDerivative · entry 1 Ryan Jason · CIK 0001585017 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,836 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on June 30, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $36.85 to $40.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. F3 · balance_after: The reporting person previously reported restricted stock units granted to the reporting person on July 15, 2015 in Table I of the Form 4 filed on July 17, 2015. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.